// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Promising Maternal and Fetal Therapeutic Outcomes from Sildenafil and Dalteparin Treatments in a Murine Pregnancy Loss Model

K. Khalaj - Society of Thrombosis and Hemostasis Research (GTH/ISTH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Spontaneous abortion

Nitric oxide

Until what age should we worry about inhibitors? New data from the PedNet Registry on 1,038 PUPs with severe hemophilia a followed from the first until over 1,000 exposure days

M. van den Berg - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

The Web‐Accessible Population Pharmacokinetics Service–Hemophilia (WAPPS‐HEMO) contribution to tailoring treatment in children: Examples for hemophilia A and B

C. H. T. Yeung - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Antihemophilic factor recombinant

Incidence of inhibitors in previously untreated patients with severe haemophilia a treated with rFVIIIFc: The PUPs A‐LONG study

C. Knigs - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIIIFc

How can a patient choose between all of the available therapies?

D. Page - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

Why and how do inhibitors develop in haemophilia A and B?

D. Matino - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

FVIII

ICHEC: Refining the pediatric bleeding assessment tool

B. Peters - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Assessment of clotting activity of recombinant FIX‐Fc fusion protein in French haemostasis laboratories

C. Pouplard - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Alprolix Intravenous

Impact of acute and chronic pain on the EQ‐5D: Insights from the PROBE study

D. Noone - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Chronic pain

N/A

Predictors for acute and chronic pain in patients with severe haemophilia in the PROBE cohort

D. Noone - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Chronic pain

N/A

Physical activity in persons with hemophilia (PwH) from France (FR), Italy (ITA), and United States (US) from the hemactive patient survey

D. Nugent - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

The WFH world bleeding disorders registry

G. Pierce - European Association for Haemophilia and Allied Disorders (EAHAD) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Using individual pharmacokinetic parameters on octocog alfa to predict individual pharmacokinetic parameters on efmoroctocog alfa in persons with hemophilia A

J. Yu - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Antihemophilic factor recombinant

“Problem Joint” a more patient relevant definition for joint morbidity in haemophilia

J. O'Hara - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

Improvements in joint health during long‐term use of recombinant factor VIII Fc fusion protein prophylaxis in subjects with haemophilia A

J. Oldenburg - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

Recombinant Factor VIII

Part‐time employment and early retirement in people with severe haemophilia: Insights from the PROBE study

M. W. Skinner - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Chronic pain

N/A

Online education improves healthcare providers’ knowledge regarding the principles of gene therapy for hemophilia

S. Hurst - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

Safety and efficacy of pdVWF/FVIII in patients with von Willebrand disease undergoing surgery: Results from a non‐interventional multicentre study

K. Khair - European Association for Haemophilia and Allied Disorders (EAHAD) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

FVIII

The role of regional surveillance networks in enhancing global outbreak reporting

E. Joh - International Congress on Infectious Diseases (ICID) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Virulence Factor RNA Transcript Expression in Cultured Clinical Isolates of Leishmania Does Not Vary by Host Age

A. Mukkala - International Congress on Infectious Diseases (ICID) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Cysteine Hydrochloride

Copyright © 2026. QuantiNova All rights reserved